NGR008: A Phase II Study of NGR-hTNF Administered as Single Agent Every 3 Weeks or Weekly in Patients Affected by Advanced or Metastatic Hepatocellular Carcinoma (HCC) Previously Treated With no More Than One Systemic Therapeutic Regimen.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2014
At a glance
- Drugs NGR-TNF (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors MolMed
- 03 Jun 2013 Data were presented at the 49th ASCO annual meeting, according to a MolMed media release.
- 03 Jan 2012 Additional lead trial investigator (Antonio Lambiase) identified as reported by ClinicalTrials.gov.
- 22 Sep 2010 Status changed from active, no longer recruiting to completed, according to a MolMed media release..